Tagrisso 80 mg is a prescription anticancer medicine containing osimertinib, a targeted therapy used in specific treatment settings involving epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Although the medicine targets particular cancer-related signaling pathways, it can still cause adverse reactions that require medical attention.
Understanding safety information is an important part of treatment. Patients should know which symptoms to report, which medical conditions to discuss before starting therapy, why monitoring matters and how other medicines may affect their treatment plan.
This page provides a general overview of important safety considerations. It does not replace the current official prescribing information or the advice of the patient’s oncology team.
1. Use Tagrisso Only Under Medical Supervision
Tagrisso should be prescribed and monitored by a qualified healthcare professional experienced in cancer treatment. The decision to use osimertinib depends on the patient’s diagnosis, molecular test results, disease stage, previous treatments and applicable treatment indication.
Patients should follow their individual prescription and the instructions supplied with their medicine. They should not start treatment based solely on online information, use another person’s medicine or independently change their dose.
Before treatment begins, the healthcare team should explain the expected treatment objectives, possible adverse reactions, monitoring requirements and circumstances in which the patient should seek urgent care.
2. Important Pulmonary Safety Warning
Osimertinib can cause interstitial lung disease (ILD) or pneumonitis, conditions involving inflammation or injury in lung tissue. These reactions can be serious and may require treatment interruption or discontinuation according to the applicable prescribing information.
Patients should promptly report new or worsening shortness of breath, persistent cough, fever or other unexplained respiratory symptoms. Such symptoms may have several causes, including infection or progression of the underlying disease, so professional assessment is important.
Do not assume that new breathing problems are a normal part of treatment. Severe breathing difficulty or rapidly worsening respiratory symptoms require emergency medical attention.
3. Heart Rhythm Changes and QT Prolongation
Osimertinib may prolong the QT interval, an electrical measurement associated with the heart’s rhythm. In susceptible patients, significant QT prolongation can increase the risk of serious rhythm disturbances.
The healthcare professional should review the patient’s cardiac history, relevant laboratory results and other medicines that may affect heart rhythm. Electrocardiography and assessment of electrolytes may be appropriate in patients with particular risk factors or when required by the prescribing information.
Patients should report fainting, palpitations, a rapid or irregular heartbeat, dizziness associated with possible heart rhythm changes or other concerning cardiac symptoms. Severe symptoms, particularly fainting with chest pain or breathing difficulty, require urgent assessment.
4. Cardiomyopathy and Heart Function
Cardiomyopathy, a condition affecting the heart muscle, is another important potential risk associated with osimertinib. Changes in heart function may require medical investigation and changes to treatment.
Patients should inform their healthcare team about a history of heart failure, cardiomyopathy or other significant cardiac conditions. The clinician will determine whether heart-function assessment is appropriate before and during treatment.
New swelling, unexplained worsening fatigue, breathlessness or other symptoms that could indicate changes in heart function should be reported promptly. These symptoms are not specific to cardiomyopathy and require assessment to determine their cause.
5. Eye Problems and Keratitis
Osimertinib may cause eye-related adverse reactions, including keratitis, which is inflammation of the cornea. Patients should report eye pain, redness, light sensitivity, excessive tearing or changes in vision.
Eye symptoms should not be ignored simply because they appear mild at first. A healthcare professional can determine whether an examination or referral to an eye specialist is needed.
Sudden visual changes, severe eye pain or significant deterioration in vision require urgent medical assessment.
6. Aplastic Anemia and Blood-Related Concerns
Aplastic anemia is a rare but serious potential adverse reaction associated with osimertinib. It involves impaired production of blood cells by the bone marrow and can have serious consequences.
Patients should tell their healthcare team about unusual bruising, unexplained bleeding, marked weakness, unusual infections or other symptoms that raise concern about a blood disorder.
These symptoms can have many causes and cannot be diagnosed from a website. The healthcare professional will decide whether laboratory testing or other investigation is necessary and how treatment should be managed.
7. Common Side Effects
Commonly reported adverse reactions include:
- Diarrhea.
- Skin rash.
- Dry skin.
- Nail changes or inflammation around the nails.
- Mouth inflammation or sores.
Some patients may experience symptoms that affect appetite, comfort or daily activities. The severity and duration of side effects vary.
Patients should report persistent diarrhea, difficulty maintaining hydration, worsening rash, painful nail changes or mouth sores that interfere with eating and drinking. Early communication can help the healthcare team assess the symptoms and recommend appropriate management.
Patients should not begin additional medicines or supplements to treat side effects without checking whether they are suitable during cancer treatment.
8. Drug Interactions
Before prescribing Tagrisso, the healthcare professional should review all medicines the patient takes. Some combinations may increase specific risks, particularly when other medicines affect heart rhythm or contribute to overlapping adverse effects.
Patients should provide a complete list of prescription medicines, nonprescription products, vitamins, herbal remedies and supplements. They should also inform their healthcare team whenever another clinician prescribes a new medicine.
Do not stop a prescribed medicine or add a supplement independently. A pharmacist or oncology professional can assess the potential interaction and explain whether any additional precautions are required.
9. Pregnancy and Breastfeeding Precautions
Osimertinib may cause fetal harm. Patients who are pregnant, planning pregnancy or who think they may be pregnant should contact their oncology team promptly.
The treating healthcare professional should explain the relevant pregnancy-prevention precautions and requirements for patients and their partners according to the current official prescribing information.
Breastfeeding also requires specific medical guidance because the medicine may pose a risk to a nursing infant. Patients should discuss the applicable restrictions before starting treatment or making changes to their feeding plans.
10. Medical Conditions to Discuss Before Treatment
Before starting Tagrisso, patients should disclose relevant medical conditions and previous treatment experiences. Important information may include:
- Previous heart rhythm problems or significant heart disease.
- A history of lung disease or prior drug-related pulmonary reactions.
- Existing eye conditions or significant visual symptoms.
- Previous serious reactions to medicines.
- All medicines and supplements currently being used.
- Pregnancy, pregnancy planning or breastfeeding, where relevant.
This information helps the healthcare team assess potential risks and determine what precautions or monitoring may be appropriate.
11. Monitoring During Treatment
Safety monitoring is individualized. Depending on the indication and the patient’s medical history, the oncology team may recommend clinical assessments, imaging, laboratory tests, electrocardiography or evaluation of heart function.
Patients should attend scheduled appointments and follow the monitoring plan provided by their healthcare professional. They should not skip recommended assessments simply because they feel well.
The healthcare team may also review adherence, other medicines, emerging side effects and whether the treatment continues to meet the patient’s clinical needs.
12. What to Do if a Serious Side Effect Is Suspected
If a patient develops a concerning symptom, they should contact their healthcare team promptly and describe when it began, how severe it is and whether it is getting worse.
Potentially serious symptoms include new breathing difficulties, persistent cough, fainting, a rapid or irregular heartbeat, significant eye pain and sudden visual changes. Severe or rapidly worsening symptoms require emergency assistance.
Patients should not attempt to diagnose a serious adverse reaction themselves or wait for a routine appointment when urgent assessment is needed. Treatment interruption or discontinuation should be managed according to the clinician’s assessment and the official prescribing information.
13. Safe Storage and Product Handling
Store Tagrisso according to the instructions provided with the specific product. Check the expiry date and keep the medicine out of the reach of children.
Do not take tablets if the product is expired, damaged or of uncertain identity. If the packaging appears tampered with or the medicine may have been exposed to unsuitable storage conditions, ask a pharmacist for advice before use.
A package photograph, printed logo or barcode alone cannot conclusively establish product authenticity. Obtain prescription medicines through legitimate supply channels and seek professional help if there are concerns about a product’s origin.
14. Frequently Asked Safety Questions
Is Tagrisso safe for every patient with lung cancer?
No. It is intended for specific clinical settings involving certain EGFR mutations. Eligibility and safety depend on individual clinical factors and the applicable treatment indication.
Should I stop taking Tagrisso if I develop diarrhea?
Do not make an independent treatment decision. Contact your healthcare team for advice, especially if diarrhea is persistent, severe or associated with dehydration. Follow the instructions provided for your specific treatment.
Can I take herbal supplements with Tagrisso?
Do not assume that a supplement is safe because it is described as natural. Discuss all supplements and herbal remedies with your pharmacist or oncology team before use.
Do I need heart monitoring?
The appropriate monitoring plan depends on the prescribing information, medical history and other risk factors. Your healthcare professional can determine whether electrocardiography, laboratory testing or assessment of heart function is needed.
What should I do if I experience breathing problems?
Seek prompt medical assessment for new or worsening breathing difficulties or persistent cough. Severe shortness of breath requires emergency care.
Conclusion
Tagrisso 80 mg is a targeted anticancer medicine that requires careful prescribing, patient education and ongoing monitoring. Important safety considerations include pulmonary toxicity, QT prolongation, cardiomyopathy, eye problems, rare blood-related complications, common side effects and potential drug interactions.
Patients should understand their prescribed regimen, provide an accurate medical and medication history, attend follow-up appointments and report new symptoms promptly. They should seek emergency assistance for severe or rapidly worsening symptoms.
Medical Disclaimer: This page provides general educational information and does not replace professional medical advice, diagnosis, treatment or the current official prescribing information. The safety profile and required precautions must be assessed by a qualified healthcare professional for each patient. Never change or discontinue prescribed treatment without appropriate medical guidance, except when following emergency instructions from a qualified clinician or emergency service.